Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://nnw.fm/Geyg4) (http://nnw.fm/Ap7Zx). Published in Advances in Therapy, a peer-reviewed medical journal, the human clinical study evaluated CBD delivery and effectiveness using LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules.
Key findings highlighted in the publication included the following:
CBD in-plasma levels with the TurboCBD 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05);
Only the TurboCBD 90 mg dose was elevated (i.e., greater than placebo) at 30 minutes (p < 0.05) and remained elevated (i.e., greater than placebo) at 4 hours (p < 0.01);
Mean arterial blood pressure (MAP) in a subgroup analysis was significantly decreased with only the TurboCBD 90 mg dose relative to baseline (p < 0.05); and
Cerebral perfusion analyzed by an index of conductance in the middle cerebral artery (MCA) in this subgroup was significantly higher with only the TurboCBD 90 mg dose relative to baseline (p < 0.001).
The key study was conducted and well tolerated in a dozen healthy young male athletes, with researchers concluded that additional studies were called for. Specifically, the report notes that “further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability.”
Already the owner of more than 60 patent applications worldwide, Lexaria was recently granted two patents for “treating certain conditions including but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia” and others. The key findings from this most recent study may prove timely, considering the demonstrated effectiveness of DehydraTECH technology in increasing cerebral blood flow and perhaps providing increased efficiency at delivering certain drugs to the brain.
In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve
Lexaria’s DehydraTECH drug-delivery technology improves the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://nnw.fm/Geyg4) (http://nnw.fm/Ap7Zx). Published in Advances in Therapy, a peer-reviewed medical journal, the human clinical study evaluated CBD delivery and effectiveness using LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules.
Key findings highlighted in the publication included the following:
CBD in-plasma levels with the TurboCBD 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05);
Only the TurboCBD 90 mg dose was elevated (i.e., greater than placebo) at 30 minutes (p < 0.05) and remained elevated (i.e., greater than placebo) at 4 hours (p < 0.01);
Mean arterial blood pressure (MAP) in a subgroup analysis was significantly decreased with only the TurboCBD 90 mg dose relative to baseline (p < 0.05); and
Cerebral perfusion analyzed by an index of conductance in the middle cerebral artery (MCA) in this subgroup was significantly higher with only the TurboCBD 90 mg dose relative to baseline (p < 0.001).
The key study was conducted and well tolerated in a dozen healthy young male athletes, with researchers concluded that additional studies were called for. Specifically, the report notes that “further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability.”
Already the owner of more than 60 patent applications worldwide, Lexaria was recently granted two patents for “treating certain conditions including but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia” and others. The key findings from this most recent study may prove timely, considering the demonstrated effectiveness of DehydraTECH technology in increasing cerebral blood flow and perhaps providing increased efficiency at delivering certain drugs to the brain.
In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve
Lexaria’s DehydraTECH drug-delivery technology improves the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
